In this episode (19.51 min), Medicom’s correspondent covers 6 presentations from the 63rd American Society of Hematology (ASH 2021) which was held as a hybrid event based in Atlanta, Georgia USA, 11-14 December 2021.
- Fitusiran meets primary endpoint in ATLAS-A/B trial
Fitusiran prophylactic therapy reduced the annual bleeding rate (ABR) in patients with severe haemophilia A or B without inhibitors. An increase in quality of life was associated with fitusiran therapy. Moreover, fitusiran offers a reduced treatment burden compared with factor replacement therapy. No new safety issues of this agent emerged. - POLARIX: Novel regimen superior to R-CHOP in diffuse large B-cell lymphoma
Polatuzumab vedotin added to rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) outperformed the standard-of-care regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as initial treatment in patients with diffuse large B-cell lymphoma (DLBCL). The safety profiles of the 2 regimens were comparable. These results suggest that Pola-R-CHP may be the preferred first-line therapy in this population. - rFVIIIFc establishes rapid tolerization in haemophilia A with inhibitors
Recombinant factor VIII Fc protein (rFVIIIFc) therapy realised immune tolerance in approximately 2 out of 3 patients with severe haemophilia A and high-titre inhibitors who underwent immune tolerance induction (ITI) therapy for the first time. In addition, the agent displayed a swift time to tolerization and no relapses occurred in this population. These results add to optimisation of ITI therapy, with the purpose of eradicating inhibitors in these patients [1]. - Heavily pre-treated FLT3-mutated AML population may benefit from novel triplet regimen
A combination treatment of quizartinib plus venetoclax plus decitabine was highly active in patients with relapsed/refractory FLT3-ITD-mutated acute myeloid leukaemia (AML). Patients with RAS/MAPK and FLT3-F691L mutations displayed treatment resistance. The safety profile of this combination did not show unexpected issues. - TRIMM-2: favourable results of talquetamab plus daratumumab for multiple myeloma
Talquetamab plus daratumumab demonstrated durable and deep responses in heavily pre-treated patients with refractory multiple myeloma (MM). Furthermore, the combination regimen was tolerable and did not show overlapping toxicity. This novel dual therapy is therefore a promising option for the treatment of patients with MM. - Benefits of eprenetapopt plus azacytidine for TP53-mutant MDS and oligoblastic AML
The combination therapy of eprenetapopt plus azacytidine showed favourable efficacy and safety in patients with TP53-mutant myelodysplastic syndrome (MDS) and oligoblastic acute myeloid leukaemia (AML). Patients with biallelic TP53 mutations or complex karyotype at baseline, a high-risk subpopulation, had higher complete response rates than patients who do not display these features.
Enjoy listening!
Copyright ©2021 Medicom Medical Publisher
Posted on
Previous Article
« Benign adrenal tumors often overproduce cortisol, may raise hypertension, diabetes risks Next Article
Gene therapy for beta-thalassemia safe, effective up to 8 years, but concerns emerge »
« Benign adrenal tumors often overproduce cortisol, may raise hypertension, diabetes risks Next Article
Gene therapy for beta-thalassemia safe, effective up to 8 years, but concerns emerge »
Table of Contents: ASH 2021
Featured articles
Acute Lymphoblastic Leukaemia
New Interfant protocol includes blinatumomab for KMT2A-r ALL
Persistent disparities in ALL health outcomes
EWALL-INO: Inotuzumab ozogamicin promising as first-line therapy for BCP-ALL
UKALL 2003: Therapy de-escalation safe in low-risk MRD patients with ALL
Acute Myeloid Leukaemia
AMLSG 16-10: Long-term benefits of midostaurin for FLT3-ITD-mutated AML
Comparable effectiveness of CPX-351 and venetoclax plus HMA in older AML patients
Promising frontline triplet regimen for TP53-mutated AML
Encouraging results of novel triplet combination for AML
Heavily pre-treated FLT3-mutated AML population may benefit from novel triplet regimen
Benefits of eprenetapopt plus azacytidine for TP53-mutant MDS and oligoblastic AML
Improved risk stratification in MDS via gene-based scoring system
Chronic Leukaemia
CAPTIVATE: Ibrutinib plus venetoclax shows ongoing efficacy in CLL
SEQUOIA: Zanubrutinib meets primary endpoint for treatment-naĂŻve CLL/SLL
Investigational therapies superior to standard-of-care in double-exposed CLL
Multiple Myeloma
GRIFFIN: Sustained responses of daratumumab plus RVd in MM
MajesTEC-1: Teclistamab efficacious in heavily pre-treated MM
iStopMM: Smouldering MM highly prevalent in general population
Mechanisms of D-KRd treatment failure in MM identified
TRIMM-2: Favourable results of talquetamab plus daratumumab for MM
Lymphoma
Second-line tisa-cel similar to standard-of-care for R/R aggressive non-Hodgkin lymphoma
Axi-cel improved event-free survival in R/R DLBCL
Axi-cel more effective but tisa-cel less toxic in DLBCL
POLARIX: Novel regimen superior to R-CHOP in DLBCL
Novel non-invasive biomarker ctDNA shows value in CNS lymphoma
Myeloproliferative Neoplasms
Mechanisms behind TP53 mutations revealed in myeloproliferative neoplasms
JAK2V617F variant allele frequency prognostic of venous events in polycythaemia vera
Immune Thrombocytopenia
Promising results of tacrolimus plus dexamethasone for ITP
Sustained remission after TPO-RA discontinuation in chronic ITP
Haemophilia
Fitusiran meets primary endpoint in ATLAS-A/B trial
ATLAS-INH: Impressive results of fitusiran for haemophilia with inhibitors
rFVIIIFc establishes rapid tolerisation in haemophilia A with inhibitors
Clonal Haematopoiesis
Reduced risk of Alzheimer’s disease in CHIP carriers
Lifelong patterns of clonal haematopoiesis revealed
Related Articles
February 4, 2022
Reduced risk of Alzheimer’s disease in CHIP carriers
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy